vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Invesco Mortgage Capital Inc. (IVR). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $10.7M, roughly 2.0× Arbutus Biopharma Corp). Invesco Mortgage Capital Inc. runs the higher net margin — 242.2% vs 23.5%, a 218.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 55.4%). Over the past eight quarters, Invesco Mortgage Capital Inc.'s revenue compounded faster (74.2% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
ABUS vs IVR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $21.3M |
| Net Profit | $2.5M | $51.5M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | — |
| Net Margin | 23.5% | 242.2% |
| Revenue YoY | 522.2% | 55.4% |
| Net Profit YoY | 112.7% | 1368.7% |
| EPS (diluted) | $0.01 | $0.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $17.6M | ||
| Q2 25 | $10.7M | $17.7M | ||
| Q1 25 | — | $18.8M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $7.5M | ||
| Q2 24 | — | $8.6M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | $51.5M | ||
| Q3 25 | — | $53.5M | ||
| Q2 25 | $2.5M | $-23.3M | ||
| Q1 25 | — | $19.6M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $40.7M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $29.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 242.2% | ||
| Q3 25 | — | 303.6% | ||
| Q2 25 | 23.5% | -131.6% | ||
| Q1 25 | — | 104.4% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | — | 542.2% | ||
| Q2 24 | — | -155.9% | ||
| Q1 24 | — | 415.9% |
| Q4 25 | — | $0.72 | ||
| Q3 25 | — | $0.74 | ||
| Q2 25 | $0.01 | $-0.40 | ||
| Q1 25 | — | $0.26 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | — | $-0.38 | ||
| Q1 24 | — | $0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $56.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $797.5M |
| Total Assets | $103.3M | $6.5B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $56.0M | ||
| Q3 25 | — | $58.5M | ||
| Q2 25 | $37.4M | $59.4M | ||
| Q1 25 | — | $42.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $48.3M | ||
| Q2 24 | — | $58.8M | ||
| Q1 24 | — | $59.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $797.5M | ||
| Q3 25 | — | $769.6M | ||
| Q2 25 | $83.0M | $709.4M | ||
| Q1 25 | — | $759.2M | ||
| Q4 24 | — | $730.7M | ||
| Q3 24 | — | $857.0M | ||
| Q2 24 | — | $759.2M | ||
| Q1 24 | — | $785.6M |
| Q4 25 | — | $6.5B | ||
| Q3 25 | — | $6.0B | ||
| Q2 25 | $103.3M | $5.4B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | — | $5.7B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $5.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $157.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | 3.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $157.1M | ||
| Q3 25 | — | $37.3M | ||
| Q2 25 | $-15.7M | $40.6M | ||
| Q1 25 | — | $19.3M | ||
| Q4 24 | — | $183.2M | ||
| Q3 24 | — | $30.8M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $57.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3.05× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 52.24× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
